I would say it's mostly a change in investment strategy. I can HODL these biotech assets from an average of 20 cents, but the reality is these biotech assets have definitely not bottomed and there is further downside. Would I hold something from 20 cents all the way to 4 cents? or should I sell at 12 cents and buy back in at 4 cents?
Also, a big rationale for my change in sentiment was finding more information regarding how CLTX CAR-T will perform in this indication. I've posted my findings on TransMolecular's 131-I TM-601 and how they fared in GBM in the past and with the trial completion and data updates coming in soon, that is not a risk I'm willing to take. CAR-T on solid tumours without any combination therapy to mitigate the TME is not a recipe for success.
I can change my investment thesis as I find more information. If the data is good and proves me wrong, I would buy back in. If this is undervalued, a 2x in the price would only bring this stock to an 80M market cap and that is still undervalued.
- Forums
- ASX - By Stock
- CHM
- Charting Only
Charting Only, page-113
-
-
- There are more pages in this discussion • 340 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CHM (ASX) Chart |
Day chart unavailable